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Summary 
The search for the optimal dental implant surface for osseointegration 
Research and development for an optimal interface between bone and dental or 
medical implants has taken place for many years. The search for the ʻbestʼ surface 
topography that improves the capacity for anchorage of bone has been on-going. 
The predictability for an accepatable treatment outcome has been shown to be very 
good for implants machined with a turning process, and also with surface 
modifications through acid etching, blasted surface or coating with hydroxyapatite. 
 
In order to determine if a new implant material or modification to the surface 
conforms to the requirements of bio-functionality, biocompatibility and safety 
specified by the International Organization for Standardization (ISO) and the 
Organization for Economic Co-operation and Development (OECD) guidelines on 
implant material and various surface treatments, it must undergo rigorous testing 
both in vitro and in vivo.  
 
The use of animals to test for products to be used in humans 
Results from in vitro studies can be difficult to extrapolate to the in vivo situation. 
For this reason the use of animal models is often an essential step in the testing of 
implant materials prior to clinical use in humans. However, no species fulfils the 
requirements of an ideal animal model1. 
The Code of Ethics of the International Association for Dental Research (IADR) 
(adopted May 2009) provides a set of guiding principles to promote exemplary 
ethical standards in research and scholarship by investigators.  
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The guidelines on animal research requires every effort must be made:  
(a) to replace the use of live animals by non-animal alternatives;  
(b) to reduce the number of animals used in research to the minimum required for 
meaningful results; and  
(c) to refine the procedures so that the degree of suffering is kept to a minimum. 
 
It has been found that animals have not been treated humanely and do suffer 
tremendous suffering physically and mentally in laboratories. The call for 
alternatives to usng animals for research has been increasing over the years. 
The poor state of animals in research laboratories has been reported previously2 
and efforts are on-going to identify and remedy the conditions the animals are 
being held3. The call for alternatives to using animals for research has gained pace 
from 1980s based on the Three Rʼs of Russel and Burch (Reduction, Refinement, 
Replacement). Government efforts on calls to alternatives has also increased4. 
 
Worldwide it is estimated that the number of vertebrate animals used annually 
ranges from the tens of millions to more than 100 million5. Government funded 
animal testing costs U.S. taxpayers over $12 billion annually6. The fact that months 
or years of human studies are also required suggests health authorities do not trust 
the results. In 2004, the FDA reported that 92 out of every 100 drugs that 
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The present study 
Due to the limitations of animal studies for products to be used in humans, we 
embark on a pilot study of using human embryonic stem cells (hESCs) progenies to 
assess the cytotoxicity and osteogenesis of various dental implant surfaces. 
 
hESC H9 line (Wicell Research Institute Inc. Agreement No. 04-W094, Madison, 
Wisc. USA) derived fibroblasts and osteoblasts were examined on 4 different 
implant surfaces. The surface modification types used in this study are: 
 1. Sand grit titanium (Ti) 
 2. Acid etch titanium (Etch) 
 3. Soluble Blast Material (SBM) 
 4. Hydroxyapatite (HA) coated 
Cytotoxic response of the differentiated hESC fibroblastic progenies were tested by 
FDA/PI staining and MTS assay.  
Osteogenesis performance was measured by bone-alkaline phosphatase (ALP) 
and osteocalcin (OC) secretion and mineral deposit by differentiated osteoblasts. 
 
In summary, the objectives of this research is to study: 
1. Is there a possibility to extrapolate in-vitro studies of implant materials to 
humans without going through animal studies? 
2. Can we identify and develop a better alternative to existing implant materials 
or modification of the surface to improve bone adhesion growth on the implant 
surface? 
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1.1 Dental Implant Surface and Osteogenesis 
The implant surface has been recognized to be a critical factor for the achievement of 
osseointegration8. Surface properties of the dental implant affect various 
physiological and chemical processes such as protein adsorption, cell-surface 
interaction and cell differentiation and growth at the interface between the bone and 
the surface of the biomaterial9. 
 
In the past 20 years, the structure and topography of dental implant surfaces has 
been investigated extensively for applications in the dental implant industry10. 
Different surface modification techniques, through alteration of surface 
physicochemical, morphological, and/or biochemical properties have been 
investigated in an effort to identify the surface that best supports attachment of cells 
for osteogenic growth. The main goal of these studies was to determine whether 
bone apposition could be enhanced by new micro-rough surfaces as compared to 
the original implant surfaces. Various techniques have been used to produce 
modifications to the implant surfaces, including sandblasting, acid-etching, a 
combination of both, or hydroxyapatite coating in order to achieve better 
osseointegration in a shorter time11. These new surface modifications had 
demonstrated enhanced bone apposition in histomorphometric studies12,13. 
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This present research study will focus on current common titanium dental implant 
surface modification types and the study of cytotoxicty and ossteogenesis on these 
surfaces using hESC progenies.  
 
Of particular future interest in the dental implant surface modification techniques are 
biochemical methods of surface modification, which immobilize soluble or insoluble 
molecules on the titanium surface for the purpose of inducing specific cells and 
tissue responses.  
 
1.2 Testing of new implant surfaces: Animal and Clinical Studies  
In order to determine whether a new material conforms to the requirements of 
biocompatibility and mechanical stability prior to clinical use, it must undergo 
rigorous testing under both in vitro and then in vivo conditions. 
In vitro testing for the characterisation of bone-contacting dental implant materials is 
used primarily as a first stage test for acute toxicity and cytocompatibility to avoid 
the unnecessary suffering of animals in the testing of cytologically inappropriate 
materials. Results from in vitro studies can be difficult to extrapolate to the in vivo 
situation, and for this reason, the use of animal models is often an essential step in 
the testing of dental implants prior to clinical use in humans. 
 
In the USA, the Food and Drug Administration (FDA) recommends animal and/or 
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clinical studies for dental implants with the following features: 
a. designs dissimilar from designs previously cleared under 51O(k) 
b. lengths less than 7 mm and/or implant diameters less than 3.25 mm  
c. an angulation of the accompanying or recommended implant abutment greater 
than 30 degrees. 
Clinical investigation usually will include a randomized, well-controlled clinical trial 
designed to demonstrate the substantial equivalence of the device when used as 
described in the Indications for Use statement. For statistical purposes, the study 
should demonstrate the device is substantially equivalent to, or not inferior to the 
performance of devices with established designs. Each study arm should have a 
statistically valid number of patients. Consultation with a statistician familiar with 
medical device research statistics is highly recommended. 
 
Clinical evaluation of implants and abutments should be conducted for a minimum of 
three years with the implant under loaded conditions. Data to be evaluated 
should include such information as implant mobility, infections, broken fixtures or 
abutments, adverse events and include a detailed explanation for all patients lost to 
follow-up. Data derived from these investigations should meet the definition of valid 
scientific data as defined in 21 CFR 860.7. The studies should be conducted by 




1.3 A new era of human embryonic stem cells (hESCs) 
The first embryonic stem cells were isolated from mice in 1981 and a great deal of 
research has been undertaken on mouse embryonic stem cells. A new era of stem 
cell biology began in 1998, when the derivation of embryonic stem cells from human 
blastocysts was first demonstrated14. 
 
1.4 The advantages of human embryonic stem cells  
In light of current knowledge, human embryonic stem cells (hESCs) have 
advantages regarding potential use for basic research and stem cell based therapy. 
1. hESCs are genetically healthy and highly standardised 
2. hESCs are relatively homogenous and are pluripotent with the potential to 
generate the various cell types in the body15 
3. hESCs are presently the only pluripotent stem cell that can be readily isolated 
and grown in culture in unlimited numbers to be useful 
 
1.5 Osteogenic differentiation of hESCs 
Several reported studies achieved osteogenic differentiation of hESCs within 2D 
culture plates in vitro, and scaffolds were utilized only as carriers for implantation 
within live animals16,17,18. Three-dimensional structures have been thought to be 
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essential for bone formation within in vitro culture19. 
To our knowledge, the first study comparing the osteogenic potential of hESC within 
2D and 3D culture systems quantitatively was reported in 2007. The study 
demonstrated that 3D culture system enhances osteogenic differentiation of hESCs 
compared to conventional 2D culture in vitro20. An in vitro study demonstrated 
proliferation and differentiation of osteoblasts within 3D printed PLGA scaffolds21.  
Several types of porous scaffolds have been shown to support in vitro bone 
formation by human cells, including those made of ceramics22, native and synthetic 
polymers23,24 and composite materials25. 
 
In light of the difficulties of in vitro studies to extrapolate to the in vivo situation, the 
use of animal models is required prior to clinical use in humans. The use of animal 
models has inherent deficiencies and no species fulfils the requirements of an ideal 
animal model. The development of stem cell research, primarily human embryonic 
stem cells (hESCs) and their progenies, which has been shown to support in vitro 
bone formation in different scaffold materials, has opened the possibility of 
overcoming several essential steps in the testing of implant materials prior to clinical 
use in humans. 
 
To our knowledge, no research has been made using hESCs and their progenies to 
study bone formation on implant materials presently used in the world.  
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In summary, the aim of this study is firstly, to examine the possibility of extrapolating 
in-vitro studies of implant materials to humans using hESCs and their progenies 
without further animal studies. We hope that with the success of this model, we will 
be able to conduct research and development for an optimal interface between bone 
and implant materials in a more economical, humane and importantly, using cell 
lines of the actual host for testing of the products. Secondly, to study the possibility 
of a new modified implant surface to identify and develop a better alternative to 
existing implant materials or modification of the surface to improve bone adhesion 











Human Embryonic Stem Cells (hESCs) 




Chapter II Human Embryonic Stem Cells and their Uses  
2.1   Origin and characteristics of human embryonic stem cells 
Human embryonic stem cells (hESCs) can be derived from preimplantation embryo 
at the blastocyst stage. At this stage, which is reached after about 5 days’ embryonic 
development, the embryo appears as a hollow ball of 70-100 cells, called the 
blastocyst. The blastocyst includes three structures: 1) the outer cell layer, which will 
develop into the placenta; 2) the blastocoel, which is the fluid filled cavity inside the 
blastocyst; and 3) the inner cell mass, from which the hESCs can be isolated. 
The characteristics of human embryonic stem cells include: 
- Potential to differentiate into the various cell types in the body (more than 200 
types are known) even after prolonged culture. hESCs are referred to as pluripotent. 
- Capacity to proliferate in their undifferentiated stage. 
- Expansion of pluripotent markers Oct4, SSEA4 
 
Growing human embryonic stem cells in the laboratory26 
In order to derive the embryonic stem cells, the outer membrane of the blastocyst is 
punctured, whereupon the inner cell mass with its stem cells is collected and 
transferred into a laboratory culture dish that contains a nutrient broth known as 
culture medium. The blastocyst is thereby destroyed and cannot develop further, but 
the isolated hESCs can be cultivated in vitro and give rise to stem cell line. The stem 
cell lines can be cryopreserved and stored in a cell bank. To be successful, the 
 10 
cultivation requires, in addition to nutrient solution, so-called “feeder” cells or 
support cells. Until recently fibroblasts from mice have been used for this purpose, 
however scientists are exploring ways to propagate human ES cell lines using 
human feeder layer or even culturing human ES cells without feeder layer. This 
eliminates the risk that viruses or infectious agents in the mouse cells might be 
transmitted to the human cells. If the stem cells are of good quality and if they show 
no sign of ageing, the same stem-cell line can yield unlimited amounts of stem cells. 
Besides their broad potential for differentiation, embryonic stem cell lines have 
proved to be better able to survive in the laboratory than other types of stem cells. At 
the various points during the process of generating embryonic stem cell lines, 
various tests are carried out to examine the cells if they exhibit the fundamental 
properties of embryonic stem cells. 
 
The current advantages and limitations of human embryonic stem cells  
Human embryonic and somatic stem cells each have advantages and limitations 
regarding potential use for basic research and stem cell based therapy. 
Advantages: 
 human ES cells are relatively homogenous and they are pluripotent15,27 
 human ES cells can be readily isolated and grown in culture in sufficient 
numbers to be useful in clinical research 
The isolation of human embryonic stem cells about a decade ago marked the birth 
of a new era in biomedical research. These pluripotent stem cells possess unique 
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properties that make them exceptionally useful in a range of applications28. 
Discussions about human stem cells are most often focused around the area of 
regenerative medicine and indeed, the possibility to apply these cells in cell 
replacement therapies is highly attractive.  
 
More imminent, however, is the employment of stem cell technologies for drug 
discovery, material testing and development. Novel improved in vitro models based 
on physiologically relevant human cells will result in better precision and more 
cost-effective assays ultimately leading to lower attrition rates and safer new drugs 
and materials that are to be used in humans. 
 
Limitations: 
 A significant potential limitation on the therapeutic use of human ES cells is the 
problem of immune rejection. Because human ES cells will not normally have 
been derived from the patient to be treated, they run the risk of rejection by the 
patient’s immune system.  
 It has been argued that, because hESCs have the potential to differentiate into 
all cell types, it might be difficult to ensure that, when used therapeutically, they 
do not differentiate into inappropriate cell types or generate tumors. It is clearly 
essential to guard against these risks particularly tumorgenesis.  
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 Current methods for growing hESC lines in culture are adequate for research 
purposes, but the co-culture of hESCs with animal materials necessary for 
growth and differentiation would preclude their use in therapy. 
Scientists are now working on generating stem cell lines, which are grown on 
human feeder layer or without feeder layer and in completely defined culture 
media29. 
 
2.2 Use of hESCs in dental implant materials research 
There are presently no known research on testing of the cytotoxicity and 
osteogenesis of dental implant materials using hESCs and their progenies. 
Stem cell research has become one of the biggest issues dividing the scientific and 
religious communities around the world. To get stem cells that are reliable, scientists 
either have to use an embryo that has already been conceived or else clone an 
embryo using a cell from a patient's body and a donated egg. Either way, to harvest 
an embryo's stem cells, scientists must destroy it. Although that embryo may only 
contain four or five cells, some religious leaders say that destroying it is the 
equivalent of taking a human life. Inevitably, this issue entered the political arena. 
Stem cell research and the careers of stem cell researchers hang on a legal roller 
coaster. Although stem cells have great potential for treating diseases, much work on 
the science, ethical and legal fronts remains. 
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2.3 Processing and culture of hESCs  
In this present study, NIH-registered H9 hESC lines were cultured and passaged as 
described. Mouse embryonic fibroblasts (MEFs) were derived from embryos 
extracted from 13.5 days postcoitum mice propagate to P4. The P4 MEFs were 
inactivated by 10 mg/mL mitomycin c for 2h and plated on 0.1% gelatin-precoated 
six-well plate at a density of 1.5x105 cells per well. hESCs were then grown on the 
inactivated MEF feeder in hESC culture medium consisting DMEM/F-12 (Invitrogen, 
Carlsbad, CA), 20% knockout serum replacement (Invitrogen), 4 ng/ mL FGF-2, 1 
mM L-glutamine (Invitrogen), 1% nonessential amino acid (Invitrogen) and 0.1 
mM β-mercaptoethanol (Sigma, St Louis, MO).  
When the cells became confluent, hESCs colonies were treated with 1mg/mL 
collagenase IV (Invitrogen) for 30mins and the floating colonies were manually 
dissected into small clumps. The hESC clumps were re-plated onto inactivated MEF 
at a 1:6 splitting ratio and cultured for up to 5–6 days with daily medium change. 
 
Differentiation of H9 ebF from H9 hESCs 
hESCs were induced to form embryoid bodies (EBs) following a standardized 
protocol as described below. Dissected hESC aggregates were transferred to 
low-attachment plates (Corning, MA, NY) and cultured in suspension with EB 
culture medium similar to hESC medium except without FGF-2.  
 
Autologous H9 ebF were differentiated through EB direct-plating outgrowth system 
 14 
as described. Briefly, after 5 days in suspension culture, the EB aggregates were 
seeded onto 0.1% gelatin-coated 75cm2 flasks containing fibroblast differentiation 
medium consisting DMEM (Sigma) supplemented with 10% FBS (Biowest, Caille, 
Nuaille). The cells at this initial passage (P0) were maintained in the same flask for 
2–3 weeks to allow extensive outgrowth and differentiation, after which they were 
passaged once the cells reached more than 90% confluence using 0.05% 
Trypsin-EDTA (Invitrogen). After two passages, the morphology of H9 ebF became 
homogenous. 
 
2.4 Differentiation of hESCs into osteoblasts 
A major area in regenerative medicine is the application of stem cells in bone 
reconstruction and bone tissue engineering. This will need defined and efficient 
protocols for guiding the differentiation of stem cells into the osteogenic lineage, 
followed by their selective purification and proliferation in vitro. A study has been 
published on the protocol for differentiation of hESCs into osteoblasts30. The 
establishment of such protocols would reduce the likelihood of spontaneous 
differentiation of stem cells into divergent lineages on transplantation, as well as 
reduce the risk of teratoma formation in the case of embryonic stem cells. 
Additionally, such protocols could provide useful in vitro models for studying 
osteogenesis and bone development, and facilitate the genetic manipulation of stem 
cells for therapeutic applications. The development of pharmokinetic and 
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cytotoxicity/genotoxicity screening tests for bone-related biomaterials and drugs 
could also use protocols developed for the osteogenic differentiation of stem cells.  
 
Other studies were done to enhance the understanding of differentiation patterns 
and bone formation capacity of hESCs31. The following were determined: (1) the 
temporal pattern of osteoblastic differentiation of human embryonic stem 
cell–derived mesenchymal stem cells (hESC-MSCs), (2) the influence of a 
three-dimensional matrix on the osteogenic differentiation of hESC-MSCs in 
long-term culture, and (3) the bone-forming capacity of osteoblast-like cells derived 
from hESC-MSCs in calvarial defects. Incubation of hESC-MSCs in osteogenic 
medium induced osteoblastic differentiation of hESC-MSCs into mature osteoblasts 
in a similar chronological pattern to human bone marrow stromal cells and primary 
osteoblasts. Osteogenic differentiation was enhanced by culturing the cells on 
three-dimensional collagen scaffolds. Fluorescent-activated cell sorting of alkaline 
phosphatase expressing cells was used to obtain an enriched osteogenic cell 
population for in vivo transplantation. The identification of green fluorescence pro- 
tein and expression of human-specific nuclear antigen in osteocytes in newly 
formed bone verified the role of transplanted human cells in the bone regeneration 
process. The current cell culture model and osteogenic cell enrichment method 
could provide large numbers of osteoprogenitor cells for analysis of differentiation 












Chapter III Methods of testing Dental Implant Materials 
3.1 Past Present and Future 
Titanium is the most widely used material for dental implants due to its desirable 
properties of high biocompatibility, high stiffness, low density and strength. More 
importantly, titanium implants allows new bone to grow directly onto the surface of 
the implant without any intermediate soft tissue layer, a process called 
osseointegration. A successfully osseointegrated implant bonds directly to the 
adjacent bone and is able to within significant load and remains functional for a long 
period. It has been clinically proven that various surface treatment methods to modify 
the surface structure and topography of the dental implants can improve the rate and 
quality of implants’ osseointegration to the bone. Common modification methods 
include ways to roughen the surface of the dental implant through acid etching or 
blasting the surface or add a coating to the surface using hydroxyapatite or titanium 
beads. 
 
Biomaterials can be evaluated under in vitro conditions to provide rapid and 
inexpensive data control on biological interaction. Systematic studies performed 
using cell culture methodology continually provide important information for 
predicting how a material performs in humans and the relevance of the surface 
properties to the body reaction. In vitro tests attempts to achieve a desirable goal to 
minimize the use of animals in research32,33. 
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The study by Orsini G et al34 analysed machined implants, sandblasted and 
acid-etched implants to study the cytotoxicity of the various surfaces using L929 
mouse fibroblasts and evaluated the morphologic differences between 
osteoblast-like cells MG63 adhering to the machined, sandblasted and acid-etched 
implant surfaces. Osteoblast-like cells adhering to the machined implants presented 
a very flat configuration, while the same cells adhering to the sandblasted and 
acid-etched surfaces showed an irregular morphology and many pseudopodi. These 
morphologic irregularities could improve initial cell anchorage, providing better 
osseointegration for sandblasted and acid-etched implants. 
 
Animal studies of osteogenesis to endosteal dental implants are usually examined 
using an in vivo dog model35. One half of the implants examined were unloaded 
implants, with the remaining one half prosthodontically loaded for 6 months. 
Undecalcified mandibular implant samples were examined with both high-voltage 
electron microscopy (HVEM) stereology and routine transmission electron 
microscopy. The osseous interface to integrated implants was shown to vary in its 
morphology. Mineralized bone was observed directly apposing the implant, often 
separated from the implant by an electron-dense deposit of approximately 50nm. 
Within this densely mineralized matrix, osteocytes were routinely observed. 
Adjacent areas were shown to contain slightly wider zones of either a less dense 
mineralized matrix or, alternatively, unmineralized tissue. Other zones consisted of 
wider unmineralized matrices containing collagen fibers and osteoblasts. These 
 19 
latter zones were consistent with the appearance of an appositional type of bone 
growth. Because bone is a dynamic, actively remodeling tissue, a varied 
morphology of the support tissues to dental implant is not unexpected. Areas of 
mature bone interfacing with successfully integrated implants were demonstrated, 
as well as areas adjacent to the mature bone that were undergoing remodeling or 
mineralization.  
 
3.2 A new era of stem cell biology studies using hESC 
The first embryonic stem cells were isolated from mice in 1981 and a great deal of 
research has been undertaken on mouse embryonic stem cells. A new era of stem 
cell biology began in 1998, when the derivation of embryonic stem cells from human 
blastocysts was first demonstrated36. 
 
3.3 Culture of hESCs 
A study on the use of hESCs to be differentiated into fibroblasts was done and the 
procedures to establish the protocol was published29. 
In this study, NIH-registered H9 hESC lines were cultured and passaged as 
described. Mouse embryonic fibroblasts (MEFs) were derived from embryos 
extracted from 13.5 days postcoitum mice propagate to P4. The P4 MEFs were 
inactivated by 10 mg/mL mitomycin c for 2h and plated on 0.1% gelatin-precoated 
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six-well plate at a density of 2.5x105 cells per well. hESCs were grown on the 
inactivated MEF feeder in hESC culture medium consisting DMEM/F-12 (Invitrogen, 
Carlsbad, CA), 20% knockout serum replacement (Invitrogen), 4 ng/ mL FGF-2, 1 
mM L-glutamine (Invitrogen), 1% nonessential amino acid (Invitrogen) and 0.1 
mM β-mercaptoethanol (Sigma, St Louis, MO).  
When the cells became confluent, hESCs colonies were treated with 1mg/mL 
collagenase IV (Invitrogen) for 30mins followed by manual dissection of the floating 
colonies into small clumps. The hESC clumps were re-plated onto inactivated MEF 
at a 1:6 splitting ratio and cultured for up to 5–6 days with daily medium change. 
 
Differentiation of H9 ebF from H9 hESCs 
hESCs were induced to form embryoid bodies (EBs) following a standardized 
protocol as below. Dissected hESC aggregates were transferred to low-attachment 
plates and cultured in suspension with EB culture medium similar to hESC medium 
except without FGF-2.  
 
Autologous H9 ebF were differentiated through EB direct-plating outgrowth system. 
Briefly, after 5 days in suspension culture, the EB aggregates were seeded onto 0.1% 
gelatin-coated 75cm2 flasks with fibroblast differentiation medium consisting DMEM 
(Sigma) supplemented with 10% FBS. The cells at this initial passage (P0) were 
maintained in the same flask for 2–3 weeks to allow extensive outgrowth and 
differentiation, after which they were passaged once the cells reached more than 90% 
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confluence using 0.05% Trypsin-EDTA (Invitrogen). After two passages, the 
morphology of H9 ebF became homogenous. 
 
3.4 Test of different implant surfaces 
Since Branemark and coworkers introduced the use of screw shaped commercially 
pure (cp-Ti) titanium implants for oral rehabilitation, an increasing number of dental 
and implants are placed in patients every year. Titanium and its alloys are among 
the most commonly used implant materials, particularly for dental, orthopedic and 
osteosynthesis applications37,38. These materials are known to have a combination 
of good properties making them particularly relevant and suited for biomedical 
applications. Titanium shows a favorable combination of intrinsic properties for the 
fabrication of dental implants such as low specific weight, high strength to weight 
ratio, low modulus of elasticity, very high corrosion resistance and excellent general 
biocompatibility39. The passive oxide layer that forms on the titanium implant 
surfaces protects the underlying metal from further oxidation and allows 
osseointegration. 
Clinical success is achieved not only because of implant material but also because 
of other properties as implant design, surface treatment and quality, besides other 
implications as surgery technique, host bone quality and load bearing40. Among all 
of titanium properties one of the most important is the surface quality41. 
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Endosseous dental implants are available with various surface characteristics 
ranging from relatively smooth machined surfaces to more roughened surfaces 
created by coatings, blasting by various substances, by acid treatments, or by 
combinations of the treatments. Studies characterizing these implants and surfaces 
include in vitro experimentation, animal studies, and human clinical trials. Both 
descriptive and functional testing of the bone-implant interface includes 
histomorphometrics and biomechanical testing such as torque removal values and 
push out/pull out strength. Using these assays to evaluate and compare different 
surfaces, the data demonstrate that rough implant surfaces have increased 
bone-to-implant contact and require greater forces to break the bone-implant 
















Chapter IV  Culture and Propagation of H9 hESCs 
4.1 Culture and passage of H9 hESCs 
The H9 hESCs line was purchased from the Wicell Research Istitute Inc. 
(Agreement No.04-W094, Madison, Wisc., USA). WiCell Research Institute is a 
nonprofit research institute established in 1999 and listed on the National Institute of 
Health (NIH) stem cell registry, approved by US government-supported research 
funding to advance the science of stem cells. The organization is focused on 
enhancing and expanding the study of human pluripotent stem cells by supporting 
basic research, establishing research protocols, creating and distributing cell lines 
and supporting efforts to unlock the therapeutic potential of stem cell technologies. 
The world’s first human embryonic stem cell lines were created at UW-Madison in 
1998. The patents that govern embryonic stem cell technology are held by the 
Wisconsin Alumni Research Foundation, a private, non-profit supporting 
organization of the UW-Madison.  
 
hESC H9 line were cultured and propagated following strict conditions of Wicell 
protocols. hESC cells were propagated on mitomycin-C inactivated P4 murine 
embryonic fibroblast (MEF) cells harvested from CF-1 inbred mouse strain.  
The culture medium used for expanding MEF cells are DMEM high glucose (Sigma, 
St. Louis, MO, USA) supplemented with 10% Fetal Bovine Serum (FBS, Hyclone, 
UT, USA). The inactivated MEF feeder cells were seeded in a density of 2.5x105 
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cells per well in six-well plates 24 hours before hESCs seeding. Before seeding 
hESCs on the feeder layer, feeder cells were washed with Phosphate Buffered 
Saline (PBS, FirstBase, Singapore) and cultured in hESCs specific medium 
subsequently. The hESC culture medium consists DMEM/F12 (Gibco-BRL Inc., 
Franklin Lakes, N.J., USA) supplemented with 20% knock out serum replacement 
(KSR, serum-free formulation; Gibco-BRL Inc.), 1mM L-glutamine (GIBCO), 1% 
nonessential amino acid (GIBCO), 100mM 2-mercaptoethanol (Sigma, St Louis, Mo, 
USA), and 4ng/ml basic fibroblast growth fator (bFGF; Gibco-BRL Inc.).  
Cells were cultured on 6-well culture plates (Becton-Dickinson Inc., USA) in 
humidified 5% CO2 incubator at 37°C. The culture media were changed daily and 
the cells were passaged when confluence in about 5-7 days intervals. hESCs were 
dissociated from MEF layers by 1mg/ml of collagenase IV treatment for 5mins 
before manual scrapping using serological pipettes to smaller cell aggregate clumps. 
Clumps of cells were collected and centrifuged at 200g for 5 minutes before seeding 
for further passages or differentiation. 
 
4.2 Embryoid body (EB) fomation: 
Culture plates were trasferred from incubator and place in the biosafety cabinet. 
Spent medium were aspirated from the wells with a Pasteur pipette. One well of 
cells is left as a backup to protect against problems during the split that could 
jeopardize the culture. 1ml room temperature of 2mg/ml of type IV Collagenase IV 
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solution were added to each well to be passaged and incubated for 30 mins at 37°C. 
To confirm appropriate incubation time the culture is viewed under a microscope for 
the perimeter of the colony to appear highlighted or just slightly folded back. The 
collagenase solution is aspirated with a Pasteur pipette carefully without disturbing 
the attached cell layer. 1ml of warmed DMEM/F-12 is added gently to each well with 
a 5ml pipette and checked to ensure that the cells remain adhered to the plate and 
the medium is aspirated off. Floating H9 colonies were transferred to 
low-attachment 6 well plates (Corning Inc.Corning, N.Y., USA) in EB culture medium 
in humidified 5% CO2 incubator at 37°C. EB medium consists DMEM/F12 (Corning 
Inc. Corning, N.Y., USA) supplemented with 20% knock out serum replacement 
(KSR, serum-free formulation; Gibco-BRL Inc.), 1Mm L-glutamine (GIBCO), 1% 
nonessential amino acid (GIBCO) and 100mM 2-mercaptoethanol (Sigma, St Louis, 
Mo, USA). The culture medium was changed every 2-3 days. 3 days and 5 days 
EBs were collected by a brief centrifugation for further tests.  
 
 27 
EB formation  
H9 hESCs were grown on MEF and culture medium (Figure 4.1). After the H9 cell 
colonies were removed from the feeder cells and cultured in EB culture medium, 
dissociated H9 colonies formed globular EB aggregates with consistent morphology 
(Figure 4.2). hESCs H9 cells and H9 EBs were subjected to polymerase chain 
reaction assay. Positive expression of transcription factors Oct4 and Nanog, which 
are essential for test for pluripotency were confirmed in all groups (Figure 4.3).  
 
Figure 4.1 ES on MEF (40x magnification) 
 
Figure 4.2 EB aggregates (40x magnification) 
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4.3 Pluripotency of H9 hESCs: 
To ensure the H9 cells subject to differentiation for the implant tests are pluripotent, 
pluripotency tests are performed prior to the research study.  
There are basically 3 criteria for the pluripotency of hESCs: 
1. Cells should have distinct margin from feeder layers when cultured in 2-D 
2. Cells should express pluripotency markers Oct4, SSEA and Nanog.  
3. The cells should be able to form teratomas when injected into animal models 
and able to differentiate into cells from all primary 3 germ layers namely endoderm, 
mesoderm and ectoderm42. 
Polymerase chain reactions for pluripotent markers: 
Undifferentiated hESCs H9 colonies were washed with PBS for three times and 
subsequently detached from mouse feeder layer by treatment of 2mg/ml 
collagenese IV for 30mins. The floating colonies were collected and washed with 
PBS for three times again. Total mRNA was extracted from the collected H9 cells 
and 5 days EB colonies using RNeasy Kit (QIAGEN, Chatsworth, CA, USA). cDNA 
was synthesized with 500ng RNA using iScript synthesis Kit (Bio-Rad, Hercules, CA, 
USA). 
Primers used for PCR are listed below with β-actin as control. 
Gene Primer Sequence Annealing Temp 
OCT 4 F: CGR GAA GCT GGA GGA GAA GGA GAA GCT G 55C 
R: AAG GGC CGC AGC TTA CAC ATG TTC 
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NANOG F: GGC AAA CAA CCC ACT TCT GC 55C 
R: TGT TCC AGG CCT GAT TGT TC 
β-actin F: ACA GAG ACC TCG CCT TTG CC 58C 
R: ACA TGC CGG AGC CGT TGT C  
 
β-actin   
oct4     
Nanog   
Figure 4.3  PCR results for Oct4 and Nanog for 2 different samples with β-actin as 
control. From lane 1 to lane 2 are expression levels of genes for hESCs H9 colonies, 
5 days EB respectively.  
 
Immunocytochemical staining for pluripotent markers 
After washing with PBS for three times, the undifferentiated H9 colonies were fixed 
with 0.5ml of 4% (v/v) para-formaldehyde (Sigma) per well for 15 minutes at room 
temperature, followed by permeabilization for 10 minutes with 0.2% Triton X-100 in 
PBS and blocking for one hour with 5% goat serum and 2% BSA (Sigma) in PBS. 
Primary antibody rabbit anti-human Oct4 (1:200/ PBS, Santa Cruz Biotechnology 
Inc., USA) was incubated with the cells at 4°C overnight and further incubated with 
 30 
Alexa Fluor 594 goat anti-rabbit IgG secondary antibody (1:200, Invitrogen, 
California, USA) for detection. Primary antibody rabbit anti-human Stage-Specific 
Embryonic Antigen-4 (SSEA-4, 1:400) were incubated with cells without 
permeabilization and were further incubated with Alexa Fluor 488 goat anti-rabbit 
secondary antibody (1:200, Invitrogen) for detection. Gold antifade reagent 
mounting (containing Dapi, Invitrogen) was performed to stain the nucleus. Staining 
was examined under fluorescent microscope (Olympus IX70, Tokyo, Japan). 
 
4.4  Characterization of undifferentiated H9 hESC 
hESCs (H9) were cultured on mouse embryonic fibroblast (MEF) cells in the 
presence of bFGF, which was used to maintain pluripotency. H9 hESCs colonies 
were observed every day and passaged every 5-7 days once sub-confulence. Over 
a long term culture, H9 cells were capable of self-renewal and maintained clear 
margin from surrounding MEF. The expression of essential intracellular transcription 
marker Oct4 for pluripotency and hESC specific surface marker SSEA4 were 
confirmed by positive immunocytochemical staining of Oct4 (Figure 4.4a) and 
SSEA4 (Figure 4.4b). DAPI was used to stain nucleus of all cells including MEF 
feeder cells (Figure 4.5b). Phase contrast, DAPI and immunocytochemical staining 
(Oct4, SSEA4) pictures were merged together (Figure 4.5c) to differentiate H9 cell 




a) a) postive SSEA4 stain of Oct4 gene b) b) positive DAPI stain 
Figure 4.4 SSEA4 and DAPI stain of hESCs (40x magnification) 
 
  
a) postive SSEA stain of Oct4 b) positve DAPI stain 
 
 
c) merged SSEA and DAPI stain  















Chapter V Preparation of Implant sample materials and hFibroblasts  
5.1 Implant material surface preparation 
Sixty 5mm diameter titanium alloy implant discs were prepared and used in this 
study. 
Thirty (30) titanium alloy (Ti6Al4V) discs were purchased (Titan Engineering 
(Singapore) Pte Ltd). These discs were prepared and treated based on the 
established protocol of surface modification technique in the Department of 
Chemical and Biomolecular Engineering, National University of Singapore. 
All the implant discs were first polished using 600, 1200 and 2400 grid sandpaper 
and then sonicated for 10 mins in water. The carbide deposited during polishing was 
removed by sonicating the substrates in Kroll’s reagent (4.0% HF, 7.2% HNO3, 88.8% 
water) for 10 mins. The reaction was terminated by the addition of 1 N sodium 
hydroxide. The implant discs were then cleaned ultrasonically for 10 mins each in 
dichloromethane, acetone, water and placed in 40% HNO3 for 40 min for surface 
passivation.  
Fifteen (15) of the acid-treated substrates were ultrasonically cleaned with ethanol, 
acetone and water. The substrates are denoted as Titanium (Ti) substrates. 
Fifteen (15) of the polished samples were further treated with H3PO4/H2O2 for 24 
hours. The samples were then ultrasonically cleaned with ethanol, acetone and 
water. These discs are denoted as acid-etched (Etch) samples. 
1. Titanium (Ti) samples 
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 Sand grit and cleaned ultrasonically for 10 min each in dichloromethane, 
acetone, water and placed in 40% HNO3 for 40 min 
2. Acid Etched (Etch) samples  
 further treated with H3PO4/H2O2 for 24 h 
Another thirty (30) titanium alloy (Ti6Al4V) samples were sponsored by a 
commercial implant company. (Implant Direct Sybron Manufacturing LLC 27030 
Malibu Hills Rd. Calabasas Hills, CA, USA) 
Fifteen (15) samples were modified by Sand Blasting with a Resorbable Material 
(SBM), the other fifteen (15) samples were modified by coating with hydroxyapatite 
(HA). 
3. Soluble Blast Material (SBM) treated samples 









a) a) Titanium  b) b) Etch  
  
c) c) SBM  d) d) HA  






a) a) Titanium b) b) Etch 
  
c) c) SBM d) d) HA 
Figure 5.2 SEM picture of the different surfaces of the implant samples 
5.2 Sterilisation and microbial contamination test of implant samples 
The implant discs samples subjected for testing were first washed with distilled 
water to remove residual particles during manufacturing of the implant. The implants 
were then autoclaved at 121°C for 20 minutes and dried at 37°C in an oven until 
use. 
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Microbial contamination test 
Samples prior to use were placed in 24 well culture plate (Cellstar, Greiner bio-one) 
and cultured with DMEM high glucose + 10% FBS (Fetal Bovine Serum, HyClone, 
USA) at 37°C and 5% CO2 for 5 days. Microscopic examination carried out to 
examine for microbial contamination showed negative result. 
 




a) Titanium b) Etch 
c) SBM d) HA 
Figure 5.4 Contamination test for samples 
 
5.3  Fibroblast differentiation from hESC 
Culture of H9 hESCs on MEF 
The NIH-registered H9 hESC lines (Agreement No. 04-W094; WiCell Research 
Institute, Madison, WI) were cultured and passaged as below. Mouse embryonic 
fibroblasts (MEFs) were derived from embryos extracted from 13.5 days postcoitum 
mice. The MEFs were inactivated by 10 mg/mL mitomycin c for 2h and plated on 0.1% 
gelatin-precoated six-well plate at a density of 2.5x105 cells per well. hESCs were 
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grown on the inactivated MEF feeder in hESC medium consisting DMEM/F-12 
(Invitrogen, Carlsbad, CA; www.invitrogen. com), 20% knockout serum replacement 
(Invitrogen), 4 ng/mL FGF-2, 1 mM L-glutamine (Invitrogen), 1% nonessential amino 
acid (Invitrogen),  and 0.1 mM  β-mercaptoethanol (Sigma, St Louis, MO).  
When the cells became confluent, hESCs colonies were treated with 1mg/mL 
collagenase IV (Invitrogen) followed by manual dissection into small clumps. The 
hESC clumps were re-plated onto inactivated MEF at a 1:6 splitting ratio and 
cultured for up to 5–6 days and daily medium change. 
 
Differentiation of H9 ebF from H9 hESCs 
hESCs were induced to form EBs following a standardized protocol as described 
below. Dissected hESC aggregates were transferred to low-attachment plates 
(Corning, MA, NY) and cultured in suspension with EB medium consisting hESC 
medium without FGF-2.  
Autologous H9 ebF were differentiated through EB direct-plating outgrowth system. 
After 5 days in suspension culture, the EB aggregates were seeded onto 0.1% 
gelatin-coated 75cm2 flasks with fibroblast differentiation medium consisting DMEM 
(Sigma) supplemented with 10% FBS (Biowest, Caille, Nuaille). The cells at this 
initial passage (P0) were maintained in the same flask for 2-3 weeks to allow 
extensive outgrowth and differentiation, and were passaged again when the cells 
reached more than 90% confluence using 0.05% Trypsin-EDTA (Invitrogen). After 














Chapter VI Cytotoxicity testing of Implant Materials 
6.1 Cytotoxicity testing 
Immortalized cell lines and live animal models are commonly used for cytotoxicity 
screening of biomedical devices and materials. However, these assays poorly 
reflect human physiology and have numerous other disadvantages. An alternative 
may be to utilize differentiated human embryonic stem cells fibroblastic progenies 
for in vitro toxicology screening43. These were generated through random 
spontaneous differentiation within standard culture media, over several passages. 
The cytotoxic response of the differentiated hESC fibroblastic progenies (pH9) to 
mitomycin C was observed to be not only very similar to the L929 cell line, but was, 
in fact, more sensitive. At an initial seeding density of 1000 cells/well (0.33 cm2), the 
proliferation index was observed to decrease 19.0% from 1.638 to 1.326 for the 
L929 cell line, as the dosage of mitomycin C was gradually increased from 0 to 1.54 
microg/mL. By contrast, pH9 displayed a corresponding 40.5% drop in proliferation 
index from 3.713 to 2.209. At a higher seeding density of 2000 cells/well (0.33 cm2), 
the proliferation index was observed to decrease 27.0% from 1.213 to 0.885 for the 
L929 cell line, whereas pH9 displayed a corresponding 43.7% drop in proliferation 
index from 3.711 to 2.091. Hence, it is apparent that pH9 exhibited a more sensitive 
dose-response to mitomycin C compared to L929, which could be advantageous for 
cytotoxicity screening assays. Additionally, this study also demonstrated that a 
highly purified and well-defined phenotypic population of differentiated hESC 
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progenies is not necessary for high reproducibility and accuracy in cytotoxic 
response. 
 
6.2 Materials and Methods 
Cell culture 
H9ebf cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM high 
glucose, Sigma, USA) and 10% (v/v) FBS (Fetal Bovine Serum, HyClone, USA) at 
37°C and 5% CO2. The subconfluent culture was treated with 0.05% trypsin-EDTA 
solution (Sigma, USA) at 37°C for 5 minutes to detach the cells for passage or 
testings. 
For cytotoxicity testing, the implant samples were carefully placed in the center of 
the 24-well culture plate (Cellstar, Greiner bio-one) in triplicates and further 
incubated for another period fo 48 hours with 1ml of fresh media. H9 ebF cells were 
seeded at 5x104 cell/cm2 onto the implant samples and incubated for 12 hours.  
Cell viability was quantitatively analyzed with CellTitier 96 Aqueous 
Non-Radioactive Cell Proliferation Assay (MTS) kit (Promega Corp, USA) strictly 
following the manufacturer’s instructions. Colorimetric analysis was subsequently 
performed by reading at 490mm absorbance with an Infinite 200 microplate reader 
(Tecan Trading AG, Switzerland). 
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6.3 Examination of Cell Attachment through Fluorescein Diacetate (FDA ) 
staining to examine cells on implants (qualitative analysis) 
At day 14, FDA and PI staining was performed to view the cell attachment directly 
under fluorescent microscope. The implant discs were placed in 20ul of FDA/PI (1:1) 
diluted in 980ul of PBS in a total volume of 1ml for 5mins. The implants were then 
washed with PBS 3 times before viewing. FDA (green) stains the cytoplasm of cells 
and PI (red) stains the nucleus of dead cells. 
 
6.4 MTS Assay (quantitative analysis) 
MTS assay was used in this study to evaluate the cytotoxicity of h9ebf on titanium 
implants. 
The complete medium used for culturing HEPM and H9 ebF was high glucose 
DMEM supplemented with 10% FBS. Cells were allowed to proliferate in T75 
culturing flasks in the above medium until confluence for about 1 week at 37°C in 
humidified atmosphere with 5% CO2. H9 ebF cells were cultured in the DMEM F-12 
without phenol red (Invitrogen) supplemented with 10% FBS at 34°C in humidified 
atmosphere with 5% CO2. Confluent cells were then trypsinized and seeded onto 6 
well plates for testing.  
MTS assay is a standard laboratory colorimetric assay that measures the activity of 
mitrochondrial activity. Enzyme reductase fom mitochondria converts yellow MTS 
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into purple colour formazan. For this experiment, CellTiter96® Aqueous Solution Cell 
Proliferation Assay Kit (Promega) was used. MTS reagent is added to the testing 
wells in the concentration of 1:5 (MTS reagent: medium vol/vol) and incubated at 
37°C in humidified atmosphere of 5% CO2 for 4 hours. Absorbance was read at 
490mm using Infinite® 200 plate reader (Tecan group, Mannedorf, Switzerland) 
 
6.5 RESULTS 
Microscopic analysis of cytotoxicity test of titanium implants: 
Microscopy analysis revealed that H9 ebF retained normal spindle-shaped 
morphology and cell density after incubation with the titanium implant sample discs 
for 48 hours (Figure 6.1–6.4). Cells proliferated quickly on the samples. Positive 
FDA stain (green) were seen to demonstrate the cytoplasm of the cells. No negative 
red stain were seen to demonstrate the nucleus of dead cells. There was a 
difference in the density of cells between the samples, whereby the HA group 
showed a higher density compared to the rest. Also under high magnification, there 







a) Titanium b) Etch 
  
c) SBM d) HA 
Figure 6.1 FDA stain (12.5x magnification) 
 
  
a) Titanium b) Etch 
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c) SBM d) HA 
Figure 6.2 FDA stain (40x magnification) 
 
  
a) Titanium b) Etch 
  
c) SBM d) HA 
Figure 6.3 FDA stain (100x magnification)  
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a) Titanium b) Etch 
  
c) SBM d) HA 
Figure 6.4 FDA stain (200x magnification) 
Figure 6.1-6.4 Cell morphology around the testing materials. There was a higher 
density in the etch and HA samples. In the HA group, there are more cells and cells 
are spindle shaped with the other groups. 
 
MTS ASSAY (Fibroblast) 
MTS assay (CellTiter96® Aqueous Solution Cell Proliferation Assay kit. Promega 
Corp, USA) was performed. 
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Statistical analysis: 
Each experiment was performed in triplicates. Statistical analysis was performed 
using SPSS software. Statistical significance was set at 0.05 for one way ANOVA 
and Bonferroni's correction for multiple comparisons. Results of the MTS assay 
were expressed as meanstandard derivations. 
A more direct bar chart comparison of cytotoxicity between the various implant 
samples was presented (Figure 6.5) which shows no significant difference between 
the 4 samples. In summary, the results validated the non-cytotoxicity of the 4 
titanium implant samples.  
 
 















Ti Etch SBM HA
O
D Cells on disk
MTS assay of ebF attachment to various samples
 49 
6.6 Discussion 
From the above test, it can be seen that H9 ebF proliferated quickly on all 4 titanium 
sample surfaces. Positive FDA stain seen was seen more distinctly on the HA 
coated samples. No negative PI stain seen was seen, demonstrating that the 
titanium samples were not cytotoxic. In the HA coated samples, more spindle 
shaped cells were seen. The MTS assay shows no significant difference between 

















Chapter VII Osteogenesis on Implant Surface 
7.1 Osteogenesis on Implant Surfaces 
Implants are widely used as scaffold for cell attachment, growth, differentiation and 
ultimately integrate with our skeletal system. Limitation of a reliable source of test 
with self or primary cells leads to lack of reproducible testing model, resulting in 
possible disappointment in later stages of clinical testing. As a promising cell source 
for pre-clinical testing of materials and drugs and in regenerative medicine, a 
standard must be set in the use of hESCs as a model for implant testing. 
This study aims to evaluate osteogenesis of hESCs on different titanium surfaces.  
Using dental implants as an example, once an implant is placed into the body, the 
adjoining bone will interact with the surface of the load bearing implant. This process 
is called osseointegration. The success of an implant treatment depends on how 
early and stable osseointegration is achieved44. Studies have shown that the 
surface of the implants which are modified to create a roughened surface matching 
native bone extra-cellular matrix enhances osteoblast attachement to improve early 
osseointegration. Various techniques have been attempted to improve the surface 
roughness of the implant, such as blasting the surface with a resorbable material, 
acid-etching, addition of titanium beads to the surface or coating the surface with 
hydroxyapatite. The manufacturer of titanium plasma sprayed (TPS) surfaces 
recommended a healing period of 12 weeks45 and this was reduced to six to eight 
weeks with the introduction of the SLA (sand blasted and acid etched) surface46. 
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Recently, nano-hydroxyapatite (n-HA) has been widely used as a bioceramic in 
orthopaedics and dentistry due its osteoconductive properties47, which makes the 
combination of a load bearing biomaterial like titanium with the osteoconductive 
properties of n-HA very attractive. 
 
The current time required for osseointegration ranges from two to six months. This 
period might be due to the osteoprogenitor cells and/or stem cells needing a long 
time to recognize the implant surface, attach onto it, followed by proliferation and 
differentiation. The surface creation of nanotopography offers the possibility to 
optimize cell attachment as well as other cell functions, because both the substrate 
topography and the biological cues enhance the initial attachment of cells for 
osseointegration. 
 
Effects of Nanotopography on Stems cells  
Nanotopography is of critical importance in various biomedical applications. The 
nanoscale surface morphology, along with mechanical and biochemical cues, 
determines stem cell attachment, proliferation, and differentiation. Nanotextured 
scaffolds, besides providing structural support to the cultured stem cells, can also 
provide the topographical signals to influence cell differentiation, particularly through 
the nanostructural architecture provided by the fibers. Li et al showed that a 3D 
electrospun nanofibrous scaffold was capable of supporting multilineage 
differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages48. 
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Stem cells use transmembrane actin-integrin adhesion complexes as 
mechanosensors to probe the rigidity of the extracellular environment, mediate 
adhesion, trigger signaling, and remodel the ECM49. Culturing hESCs in the 
presence of actin disrupting agents proved that cytoskeleton remodelling through 
actin polymerization is critical for the morphological and proliferative behaviour of 
hESCs cultured on nanotopographic surfaces. 
 
Effect of nanotopography on embryonic stem cells 
Gerechta et al recently reported the influence of surface topography on the 
morphology and proliferation of hESCs50. They demonstrated that poly di-methyl 
siloxane substrates with nanoscale line-grating (in the range of 600 nm ridges with 
600 nm spacing and 600 ± 150 nm feature height) induced more hESC alignment 
and elongation, compared to the flat surface. These were characterized by the 
cytoskeletal proteins actin, vimentin, and tubulin. 
The utility of hESCs as a source of master cells to differentiate in to specific cell 
lines are poorly understood. However, it was generally believed that differentiation 
stimuli should be applied to cells as early as possible during diferentiation process 





7.2 Materials and Methods 
Osteogenesis using H9 hESCs:  
H9 colonies were trested with 1mg/ml collagenase IV for 5 mins and cell clumps 
were transferred to 24-well culture plates to create a mono-layer cell culture. For 
differentiation, the media used is a cocktail medium containing DMEM with 5% FBS, 
50μM ascorbate-2-phosphate (Sigma), 10mM sodium β-glycerophosphate, and 
10-8M dexamathasone (Sigma) and 1% penicillin-streptomycin solution (Invitrogen). 
 
7.3 hESC seeding 
For osteogenic differentiation in different implant samples, H9 hESCs, their specific 
cells colonies obtained through collagenase treatment were seeded onto the 
surface of the implant samples, followed by the osteogenic inducement in DMEM 
containing 10% FBS, 1-Sodium β-Glyceralphosphate (Sigma), 50ug/ml 
ascorbate-2-phosphate (Sigma), 10-8M Dexamethasone (Sigma) and 1% 
penicillin-streptomycin solution (Invitrogen). 
Immediately after cell seeding, the titanium implant sample discs embedded with 
cells were incubated in osteogenesis-inducing medium for 21 days. Culture media 
was collected from the titanium implant wells every 2 days and stored at -80°C for 
osteocalcin quantification using a Gla-type Osteocalcin ELA kit (Takara Inc., Japan) 
following the manufacturer’s instruction. Standard curve fitting was performed with a 
non-linear regression model. Concentrations of osteocalcin secretion in sample 
 55 
media were calculated based on the standard. 
 
7.4 Test and Results 
7.4.1 Confirmation test 
7.4.1.1 Alizarin Red assay (bone nodules Ca2+) 
Alizarin red staining is commonly used to examine the presence of calcium 
deposition by cells of osteogenic lineage. It is an early stage marker of matrix 
deposition which is crucial towards the formation of calcified extracellular matrix 
associated with bone. In this study, alizarin red staining was performed after 21 days 
of induction.  
At day 21, differentiated cells were washed with PBS (Ca2+/Mg2+ free) for three 
times and fixed with 4% formaldehyde (Sigma) for 20mins at room temperature. The 
plate was then rinsed with distilled de-ionized water for three times and stained with 
500μl of alizarin red working solution in each well for 5mins at room temperature 
with light protection. The working solutions were then aspirated and the plate was 
rinsed with de-ionized water thoroughly until non-specific staining was washed out. 
The plate was then air-dried and pictures were then taken under inverse microscope. 
Positive alizarin red staining was obtained for all 4 sample groups. However, alizarin 
condensation in the HA sample group was generally higher than other groups. 
(Figure 7.2 – 7.3).  
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Alizarin Red staining 
  
a) Titanium b) Etch 
  
c) SBM d) HA 





a) Titanium b) Etch 
  
c) SBM d) HA 
Figure 7.2 Alizarin stain (100x magnification) 
7.4.1.2 Total collagen assay (matrix) 
Total collagen staining to examine the matrix secretion was performed using 
SircolTM Soluble Collagen Assay kit (Biocolor, UK). 100μl of culture medium was 
collected and prepared following strictly to manufacturer’s instructions, centrifuged 
at 12,000rpm for 10mins and transferred to 96 well plate and read at absorbance of 
550nm, the as shown in Figure 7.4. Collagen concentrations were obtained from the 




Figure 7.3 Total collagen assay chart 
7.4.1.3 Immunostaining 
At day 14, the implants were incubated in the rabbit anti-human collagen I primary 
antibody (70x dilution in PBS with 0.1% BSA as recommended. Chemicon, USA) for 
45mins at room temperature. After 3 washes with 1x PGX, implants were incubated 
in Alexa Fluor 594-conjugated goat anti-rabbit IgG secondary antibody (100x 
dilution PBS with 0.1% BSA, Molecular Probes, Invitrogen) for 20mins at room 
temperature. FDA was counter stained to the implant samples after antibody 
staining. The implant samples were then washed extensively with PBS before 
fluoresecent microscopy. The results of the immunostaining assay are shown in 















a) Titanium  b) Etch  
  
c) SBM  d) HA  




a) Titanium  b) Etch  
  
c) SBM  d) HA 
Figure 7.5 Collagen RED ALP GREEN stain (40x magnification) 
  
a) Titanium  b) Etch  
  
c) SBM  d) HA  
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Figure 7.6 Collagen RED ALP GREEN stain (100x magnification) 
  
a) Titanium  b) Etch  
  
c) SBM  d) HA  
Figure 7.7 OC GREEN ALP RED stain (12.5x magnification) 
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a) Titanium  b) Etch  
  
c) SBM  d) HA  
Figure 7.8 OC GREEN ALP RED stain (40x magnification) 
  
a) Titanium  b) Etch  
  
c) SBM d) HA  
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Figure 7.9 OC GREEN ALP RED stain (100x magnification) 
7.4.1.4 RT-PCR (osteoblast gene markers) 
At day 21, differentiated cells were collected. Total mRNA was extracted using 
RNeasy® Plus Mini Kit (Qiagen, USA). Strictly following manufacturer’s instructions, 
total mRNA was extracted and quantified by Nanodrop (Nanodrop Technologies, 
Wilmington, DE). cDNA was then generated from 500ng of tRNA using iScriptTM 
cDNA Synthesis Kit (Bio-Rad Laboratories Inc. USA) following manufacturer's 
instructions. 
Real time PCR was performed using StepOne Plus (Applied Biosystems). Samples 
were denatured thoroughly at 95°C for 5mins, in each cycle of 35 cycles, the 
samples were then denatured at 95°C for 10s, followed by specific annealing 
temperature for different genes at 60°C for 1 min. PCR products were further loaded 
on 2% agarose gel electrophoresis with ethidium bromide staining. Bands were 
visualized using Universal Hood (Light Imaging System (Biorad segrate, Milan, 
Italy)). 
 
PCR primers are listed below. 
Gene Primer sequence Annealing Temp 
Runx II 
 
F:CCG CAC GAC AAC CGC ACC AT 




F: GGG GGT GGC CGG AAA TAC AT 
R: GGG GGC CAG ACC AAA GAT AG 
60°C 
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Osterix F: ACT CAC ACC CGG GAG AAG AA 
R: GGT GGT CGC TTC GGG TAA A 
60°C 
Osteocalcin F: ATG AGA GCC CTC ACA CTC CTC  
R: GCC GTA GAA GCG CCG ATA GGC 
60°C 
Col Type I F: GGA CAC AAT GGA TTG CAA GG 
R: TAA CCA CTG CTC CAC TCT GG 
60°C 
BSP  F: CAG TAG TGA CTC ATC CGA AG 
R: CTC CTC TTC TTC TTC ATC AC 
60°C 
 
Msx II CGG TCA AGT CGG AAA ATT CAG 
CGA ATA TCG GCC GGG TTC 
60°C 
 
Results: RT-PCR assay 
The RT-PCR assay shows that osteogenic gene markers were present in all the 
samples. The HA samples show a higher overall amount of osteogenic markers, 
while the Etch samples show a higher amount of Collagen I marker, and the SBM 





Figure 7.10 RT-PCR assay chart 
 
7.4.2 Media Assay 
7.4.2.1 Alkaline Phosphatase (ALP) secretion assay over 21 days 
To further investigate the role of implants on osteogenic differentiation of hESCs. 
ALP activity in media spent along the time course of differentiation was studied.  
Alkaline phosphatase is present in almost all tissues throughout of the body. 
However, it is particularly concentrated in bone, liver and placenta. We studied both 
the releasing tendency of ALP in media spent along the period of differentiation and 
the ALP level in cell lysates.  































Osteogenesis on different implant material samples
bs-ALP BSP MsxII RUNX2 Col type I Osteocalcin Osterix
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every other day and frozen immediately after collection. At day 21, activity of 
secreted alkaline phosphatase in media spent of differentiating cells was measured. 
Briefly, 100μI of alkaline phosphatase yellow liquid substrate from ELISA assay 
(Sigma catalog no. P7998) was used to monitor the activity. The reaction was taken 
in 96 well plates at room temperature for 30mins. 50μl of 3N NaOH solution were 
then added to each well to stop the reaction. The enzyme activity was detected by 
absorbance reading at 405nm. The increment of absorbance readings at 405nm 
directly reflects the AP activity within the samples. 
 
 
Figure 7.11 ALP secretion assay chart 
 
RESULT 
The HA sample showed a slight drop in ALP secretion from D1 to D5, and then a 






























with a slight increase on D19. The other three samples shows relatively stable ALP 
secretion during the period of collection from D1 to D21, except the SBM sample 
which had a peak secretion from D13 to D15 and then a reduction from D15 to D17. 
7.4.2.2 Osteocalcin (OC) secretion assay over 21 days 
Osteocalcin is non-collagenous protein secreted by osteoblast cells found in bone 
and dentin. It is generally believed to play important roles in mineralization and 
calcium homeostasis. Synthesized and secreted by osteoblast cells, osteocalcin is 
used a typical marker of osteoblast and osteogenic differentiation. Serum level of 
osteoblast increment is well correlated with bone mineral deposition. 
Similar to AP assay, 100μl of collected media was used for OC assay. 100ul of 
samples added to each well of a 96 well plate coated with osteocalcin specific 
antibodies (Gla-OC, ElA Kit, Takara, Japan). The plate was then agitated gently for 
proper mixing for 2 hours at room temperature. After 3 washings with PBS, 100μl of 
antibody-POD conjugate solution was added to each well again for 1 hour with 
gentle agitation at room temperature. Again the plate was washed for 4 times 
followed by adding 100μl of substrate solution into each well and incubated for 
15mins at room temperature. Lastly, the reaction was stopped by adding 100μl of 
1N H2SO4 into each well. Absorbance was detected at 450nm and OC concentration 





Figure 7.12 OC secretion assay chart 
 
RESULT 
OC secretion was seen to be increasing from D1 to D7. After D7 there is a relative 
phase of stable OC secretion to D17. From D17 onwards, there seems to be a 
reduction phase of OC secretion for the Ti, Etch and SBM samples, whereas the HA 
samples show and increase in OC secretion. 
 
7.4.3 Cellular and Proteomic Assay 
7.4.3.1 Total cell number 
At day 7, 14 and 21 days of differentiation, implants were washed with PBS for 3 
times followed by trypsinisation. After 5mins centrifuge at 300g, cell pellets were 





















TI Etch SBM HA
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were subjected to MTS assay. Spectral reading from this colorimetric assay was 
analysed to compare the cell growth profile among the various implant sample 
groups. 
7.4.3.2 Total protein concentration 
Cells from all four groups using different stimulation media were collected at day 21. 
Cells were rinsed twice with PBS, followed by 15mins lysis using non-denatured 
lysis buffer (20mM Tris HCl pH 8, 137mM NaCl, 1% Triton X-100 and 2mM EDTA) 
on ice with constant agitation. The lysates were then centrifuged at 14000g for 
5mins and the supernatants were used for further testing. Total protein was 
determined in cell lysates through a colorimetric assay similar to Lowry assay using 
DC protein assay kit (BioRad). Briefly, the protein samples were first incubated with 
copper tartrate solution in alkaline condition, and subsequently, reduction of a 
diluted Folin reagent was added into each well by copper-treated proteins. The 
reaction was stable from 15mins to 1 hour. Absorbance was read at 750nm using 
Infinite® 200 plate reader (Tecan group. Mannedorf, Switzerland). Following 
manufacturer instructions, total protein concentraion were estimated using a 
standard curve obtained with serial dilutions of BSA (0.15, 0.3, 0.6, 0.9, 1.2mg/ml). 
100μl of cell lysate was used for quantitation of cellular alkaline phosphatase (ALP) 
and osteocalcin (OC) concentrations using ALP and OC assay as described below. 




Figure 7.13 Total protein concentration assay chart shows relatively similar  
total protein concentration among the four sample groups. 
 
7.4.3.3 Cellular ALP concentration 
Media spent of differentiating hESCs from in vitro differentiation were collected 
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secreted alkaline phosphatase in media spent of differentiating cells was measured. 
Briefly, 100μI of alkaline phosphatase yellow liquid substrate from ELISA assay 
(Sigma catalog no. P7998) was used to monitor the activity. The reaction was taken 
in 96 well plates at room temperature for 30mins. 50μl of 3N NaOH solution were 
then added to each well to stop the reaction. The enzyme activity was detected by 
absorbance reading at 405nm. The increment of absorbance readings at 405nm 
directly reflects the AP activity within the samples. The result of the osteoblast MTS 
assay is shown in the chart below (Figure 7.15). 
Osteoblast MTS Assay 
 
Figure 7.14 Cellular ALP concentration assay chart showing higher amount of 










Ti Etch SBM HA
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7.4.3.4 Cellular OC concentration 
Similar to ALP assay, 100μl of collected media was used for OC assay. 100μl of 
samples added to each well of a 96 well plate coated with osteocalcin specific 
antibodies (Gla-OC, ElA Kit, Takara, Japan). The plate was then agitated gently for 
proper mixing for 2 hours at room temperature. After 3 washings with PBS, 100μl of 
antibody-POD conjugate solution was added to each well again for 1 hour with 
gentle agitation at room temperature. Again the plate was washed for 4 times 
followed by adding 100μl of substrate solution into each well and incubated for 
15mins at room temperature. Lastly, the reaction was stopped by adding 100μl of 
1N H2SO4 into each well. Absorbance was detected at 450nm and OC concentration 
was calculated based on the standard curve plotted when performing the 




Figure 7.15 Cellular OC concentration assay chart showing higher OC 
concentraion in HA sample compared to the other samples. 
Statistical analysis: 
Each experiment was performed in triplicates. Statistical analysis was performed 
using SPSS software. Statistical significance was set at 0.05 for one way ANOVA 
and Bonferroni's correction for multiple comparisons. Results of the MTS assay, AP 




In this osteogenesis study of the four implant sample groups using hESC derived 






















ostetoblasts. The HA samples showed higher density in the alizarin red stain assay 
and higher amount of overall osteogenic gene markers in the RT-PCR assay relative 
to the other three samples. The media secretion assay shows relatively similar 
patterns in the ALP and OC secretion. Whereas from the cellular secretion assay, it 
shows a higher amount of ALP secretion in the SBM and HA samples and a higher 

















Chapter VIII Conclusion 
The present study shows that hESC progenies, namely H9 ebF and H9 ebO are 
capable of being used to test for cytotoxicity and osteogenesis of implant material 
and their various surface modifications. 
 
In the first part of the study, we used H9 ebF to test for cytotoxicity of the various 
implant samples. The results from the FDA stain examination shows that H9 ebF 
were able to attach to all the various samples, with the HA samples showing a more 
distinct attachment than the other three samples. Under higher magnification, it can 
bee seen that the HA samples also demonstrated more spindle-shaped fibroblast 
cells than the other smaples. No negative PI stain was seen, indicating that none of 
the samples were cytotoxic. The MTS assay however shows no significant 
difference between the four samples. 
 
After the successful completion of the study to show that the implant smaples were 
non-cytotoxic, the second part of the study was carried out using hESCs to study the 
osteogenesis potential of the various samples. 
 
In the confirmation tests performed, the HA samples shows higher density in the 
alizarin red stain assay and higher amount in the total collagen assay than the other 
groups. The immunostaining assay for OC, ALP and collagen shows all four sample 
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groups showing postive result. In the RT-PCR test, the various osteogenic gene 
markers were present in all the samples. The HA samples show a higher overall 
amount of osteogenic markers, while the Etch samples show a higher amount of 
Collagen I marker, and the SBM samples show a higher amount of RUNX2 marker 
compared to the rest of the samples. 
 
In the media secretion assay, all the four samples show a relatively stable pattern of 
ALP and OC secretion, indicating positive osteogenic activity from the osteoblasts 
attached to the four samples. The HA sample showed a initial slight drop in ALP 
secretion from D1 to D5, and then a rise from D5 to D7 and then maintained a 
relatively stable secretion pattern to D21. The other three samples shows relatively 
stable ALP secretion during the period of collection from D1 to D21, except the SBM 
sample which had a peak secretion from D13 to D15 and then a reduction from D15 
to D17. OC secretion of the four samples were seen to be increasing from D1 to D7. 
After D7 there is a relative phase of stable OC secretion to D17. From D17 onwards, 
there seems to be a reduction phase of OC secretion for the Ti, Etch and SBM 
samples, whereas the HA samples showed an increase in OC secretion. 
 
In the cellular and proteomic secretion assay, all four samples show similar amount 
of total protein concentraion, while there was a higher amount of ALP secretion in 
the SBM and HA samples and a higher amount of OC secretion for the HA samples 
compared to the other samples. 
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From the cytotoxicity and osteogenesis tests performed, all the samples were 
non-cytotoxic, but in terms of osteogenic potential, it seems that the SBM and HA 





























Chapter IX Prospectives 
The prospective of this study is to focus on the potential of hESCs and their directed 
differentiation as a potential cell model in for future pre-clinical implant material 
testing for cytotoxicity and osteogenesis prior to human clinical use. The continued 
research and development of alternative surface modification methods to improve 
osteoblast cell adhesion and growth to enhance osseointegration to develop a 
better dental implant system is also an important prospect for future studies. 
 
This study shows that hESCs differentiated into fibroblasts and osteoblasts are able 
to attach and proliferate on the various implant surfaces. With the inherent 
advantages of hESCs compared to conventional testing methods, the use of 
immortalised hESC cell lines are far better cell model than other animal cell model in 
resembling normal human cell physiology in homogeneity. 
 
The derivation of differentiated human models is not only restricted to osteoblast 
lineage, it can also be used as a model in other lineages such as hepatocytes, 
cardiomyocytes and neurons also. Making hESCs as a model will certainly provide 
new insights in improving current model for pre-clinical testings and ultimately 




Gene Expression profiling to achieve direct characterisation of hESCs 
differentiation51 
Previous studies have shown that a unique network of transcription factors are 
involved in hESC self renewal. Since hESC lines have the potential to differentiate 
into cells of all three germ layers, cells derived from hESCs may be useful for the 
treatment of a variety of inherited or acquired diseases.  
 
The molecular signal required to differentiate hESC into a particular cell type has not 
been defined. It is expected that global gene expression profiling of hESC may 
provide an insight into the critical genes involved in maintaining pluripotency of hESC 
and genes that are modulated when hESCs differentiate. Several groups have 
utilised a variety of high throughput techniques and performed gene expression 
profiling of undifferentiated hESCs and mouse ES cells (mESC) to identify a set of 
genes uniquely expressed in ES cells but not in mature cells and defined them as 
"stemness" genes. These molecular techniques include DNA microarray, 
EST-enumeration, MPSS profiling, and SAGE.  
 
A set of approximately 100 genes were identified, which are highly expressed in ES 
cells and considered to be involved in maintaining pluripotency and self renewal of 
ES cells. When hESCs are differentiated, "stemness" genes are down-regulated and 
a set of genes are up-regulated. Together with down-modulation of "stemness" 
genes and up-regulation of new genes may provide a new insight into the molecular 
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pathways of hESC differentiation and study of these genes may be useful in the 
characterization of differentiated cells. 
 
Methods of hESC growth using Feeder Free Medium 
The maintenance and differentiation of hESCs is mainly dependent on the use of 
feeder cells, which are obtained from animal sources. hESCs are commonly 
cocultured with feeder layers of mouse embryonic fibroblasts (MEF). Cells grown in 
this manner are not ideal for transplantation into humans due to the risk of 
xenogenic-based rejection by the immune system52 as well as the potential for 
cross-species transfer of viruses or pathogens53. Such in vitro culturing presents 
certain theoretical hazards to the use of stem cells for regenerative medicine, such 
as the spread of viruses and other infectious agents not normally found in humans. 
However, it is believed that the nanotopographical substrates can maintain the 
proliferation of undifferentiated rhesus ESCs without the use of feeder cells54. 
MEF feeder layers can be replaced with human-derived cell lines to avoid hESC 
contact with murine cells, but the presence of additional cell lines in hESC culture 
inevitably contributes to variability and increased cost during the expansion and 
scale-up of stem cells55,56.  
As a result, direct coculture has been replaced by medium conditioning, where hESC 
are grown on an acellular support matrix in the medium that has been conditioned by 
a separate, supporting cell line57,58. 
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hESC grown in feeder-free culture require a solid growth matrix on which to 
proliferate, the most common being Matrigel™ (MAT), a complex basement 
membrane extract derived from Engelbreth-Holm-Swarm mouse sarcoma whose 
composition is not well defined59,60. MAT is used because most hESC do not grow 
well on more defined matrices like fibronectin, laminin, or collagen61,62,63.   
A simple, completely defined matrix that could support hESC growth and 
maintenance of pluripotency would provide significant advantages over the use of 
MAT or feeder layers in terms of reproducibility, scale-up, cost, and applicability to 
human therapies. Type I collagen (COL I) offers significant potential as a hESC 
growth biomatrix because it is well defined, widely available, and FDA approved for 
several applications64,65,66,67,68,69,70. 
In a more recent study, Brafman et al. utilized an array-based technology to screen 
hundreds of hESC growth microenvironments composed of various extracellular 
matrix proteins and signaling molecules. They found that optimal hESC growth 
conditions required a combination of collagen I, collagen IV, fibronectin, and 
laminin71. 
A patent application has been made for a new method of growing hESCs using a 
feeder free medium. (WIPO Patent Application WO/2011/106676). This invention 
uses a conditioned medium (CM), where the CM has reduced level of secreted 
frizzled-related protein (sFRP-1). In addition, such hESC growth can be supported 
using a Type I collagen (COL I) biomatrix. Also provided are methods to enhance 
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hESC growth and methods to reduce sFRP-1 protein levels. Methods of screening 
cell lines for reduced sFRP-1 levels and compounds that can specifically overcome 
sFRP-1 antagonism or promote wnt/β-catenin agonism are also provided. 
Alternatives to surface modification to dental implant materials 
Osteoblast cells attach, proliferate, and differentiate to the dental implant material 
and produce matrix proteins like Type 1 collagen, osteopontin, bone sialoprotein, 
osteonectin, osteocalcin, fibronectin, and BMPs before mineral deposition72-79.  
 
BMPs and matrix proteins induce bone formation in vitro and in vivo. Induction of 
bone formation by demineralized bone matrix (DBM) after implantation in muscles of 
different animals was first reported by Urist in 196580. Urist et al. later81 
demonstrated that proteins (specifically, bone morphogenetic protein, BMPs) that 
were originally present in the DBM were the osteoinductive factors. This conclusion 
was confirmed by others82-84. 
 
Engineered osteoinductivity by grafting bone growth factors, osteogenic proteins or 
peptides is especially important to apply to metal implants used in dentistry. This will 
allow faster bone formation and enhanced osseointegration of the implants with 
bone84,85, reducing the chances of implant loosening and implant failure. 
 
Legros86 has advocated the development of calcium phosphate (CaP)-based 
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biomaterials and use as bone substitute materials in dentistry due to the similarity to 
the composition of bone mineral, its biodegradability, bioactivity, and 
osteoconductivity. Interconnecting porosity similar to that of bone can also be 
introduced during the manufacturing process. 
 
More recently, combination of interconnecting macro- and microporosities87-92 and 
concavities were demonstrated to be important features of CaPs because these 
features allow adsorption, entrapment, and concentration of circulating BMPs and 
osteogenic factors and/or osteoprogenitor cells, thus imparting osteoinductive 
properties to these materials. 
 
Depositing CaP coatings on orthopedic and dental implants combine the bioactivity 
of CaP and the strength of the metal. The challenge is to determine the appropriate 
architecture (appropriate combination of microporosity and macroporosity) in 
fabricating the CaP materials to optimize the ability to entrap and concentrate 
osteogenic factors (growth factors and/ or osteoprogenitor cells) and then be able to 
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